These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 11591626)

  • 1. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
    Corti R; Burnett JC; Rouleau JL; Ruschitzka F; Lüscher TF
    Circulation; 2001 Oct; 104(15):1856-62. PubMed ID: 11591626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopeptidase inhibition: effective blood pressure control for vascular protection.
    Quaschning T; Ruschitzka F; Lüscher TF
    Curr Hypertens Rep; 2002 Feb; 4(1):78-84. PubMed ID: 11790296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction.
    Quaschning T; Galle J; Wanner C
    Kidney Int Suppl; 2003 May; (84):S54-7. PubMed ID: 12694309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
    Trindade PT; Rouleau JL
    Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopeptidase inhibitors: will they have a role in clinical practice?
    Worthley MI; Corti R; Worthley SG
    Br J Clin Pharmacol; 2004 Jan; 57(1):27-36. PubMed ID: 14678337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective effects of vasopeptidase inhibitors.
    Lapointe N; Rouleau JL
    Can J Cardiol; 2002 Apr; 18(4):415-20. PubMed ID: 11992135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopeptidase inhibition: a novel approach to cardiovascular therapy.
    Floras JS
    Can J Cardiol; 2002 Feb; 18(2):177-82. PubMed ID: 11875587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
    Daull P; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopeptidase inhibition for blood pressure control: emerging experience.
    Quaschning T
    Curr Pharm Des; 2005; 11(25):3293-9. PubMed ID: 16250856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Nawarskas J; Rajan V; Frishman WH
    Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
    Vesterqvist O; Reeves RA
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment.
    Machowska A; Juszczak K; Novak P; Thor P
    Folia Med Cracov; 2009; 50(3-4):35-42. PubMed ID: 21853869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders.
    Tabrizchi R
    Drugs; 2003; 63(20):2185-202. PubMed ID: 14498755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system.
    Regoli D; Gobeil F
    Can J Physiol Pharmacol; 2017 Oct; 95(10):1117-1124. PubMed ID: 28384411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current role of neprilysin inhibitors in hypertension and heart failure.
    von Lueder TG; Atar D; Krum H
    Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopeptidase inhibition and endothelial function in hypertension.
    d'Uscio LV; Lüscher TF
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S6-14. PubMed ID: 11716800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
    Maniu CV; Meyer DM; Redfield MM
    Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopeptidase inhibition: a new direction in cardiovascular treatment.
    Asher JR; Naftilan AJ
    Curr Hypertens Rep; 2000 Aug; 2(4):384-91. PubMed ID: 10981174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
    Kubota E; Dean RG; Hubner RA; Balding LC; Johnston CI; Burrell LM
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S31-3. PubMed ID: 11716804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.